|
|
Hokkaido University Collection of Scholarly and Academic Papers >
Hokkaido University Hospital >
Peer-reviewed Journal Articles, etc >
Efficacy and Safety of Blonanserin Oral Tablet in Adolescents with Schizophrenia : A 6-Week, Randomized Placebo-Controlled Study
| Title: | Efficacy and Safety of Blonanserin Oral Tablet in Adolescents with Schizophrenia : A 6-Week, Randomized Placebo-Controlled Study |
| Authors: | Saito, Takuya Browse this author →KAKEN DB | | Sugimoto, Saori Browse this author | | Sakaguchi, Reiko Browse this author | | Nakamura, Hiroshi Browse this author | | Ishigooka, Jun Browse this author |
| Keywords: | adolescent | | antipsychotics | | blonanserin | | schizophrenia |
| Issue Date: | 14-Feb-2022 |
| Publisher: | Mary Ann Liebert |
| Journal Title: | Journal of child and adolescent psychopharmacology |
| Volume: | 32 |
| Issue: | 1 |
| Start Page: | 12 |
| End Page: | 23 |
| Publisher DOI: | 10.1089/cap.2021.0013 |
| Abstract: | Objectives: To evaluate the short-term efficacy and safety of blonanserin in adolescents with schizophrenia.Methods: This 6-week multicenter, double-blind, randomized, placebo-controlled study investigated fixed-dose blonanserin (8 or 16 mg/day) in patients 12-18 years of age diagnosed with schizophrenia, as indicated by a Positive and Negative Syndrome Scale (PANSS) total score of 60-120 and a Clinical Global Impressions-Severity score of >= 3. The primary endpoint was change from baseline to week 6 in the PANSS total score, using a mixed model for repeated measures analysis. Safety was assessed by the incidence and severity of adverse events (AEs).Results: Among 151 randomized patients, 150 were included in the primary analysis population. Demographic and clinical characteristics were similar across groups at baseline. The rate of study discontinuation was 14.9%, 23.5%, and 28.3% in patients administered with placebo, blonanserin 8 mg/day, and blonanserin 16 mg/day, respectively. The least-squares mean change (95% confidence interval [CI]) from baseline to week 6 in PANSS total score was -10.6 (-16.10 to -5.10), -15.3 (-20.80 to -9.86), and -20.5 (-25.89 to -15.16) in patients administered placebo, 8 mg/day blonanserin, and 16 mg/day blonanserin, respectively. The 16-mg/day blonanserin group showed significantly greater reduction in the PANSS total score than the placebo group (least-squares mean difference [95% CI]: -9.9 [-17.61 to -2.25], p = 0.012, effect size: 0.538), although the 8-mg/day group showed no significant difference. The incidence of AEs such as akathisia, somnolence, and hyperprolactinemia was higher in the blonanserin groups than in the placebo group. AEs associated with blonanserin were generally mild and were consistent with its known profile in adults with schizophrenia.Conclusions: Blonanserin achieved a sufficient efficacy in adolescent patients, and the safety profile was similar to that in adults, which suggests that blonanserin may be a safe treatment option for adolescents with schizophrenia.Study registration number: Japic CTI-111724. |
| Type: | article |
| URI: | http://hdl.handle.net/2115/84466 |
| Appears in Collections: | 北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
|
